Jim Wassil - Oct 17, 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Operating Officer
Signature
Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Oct 17, 2022
Transactions value $
-$65,241
Form type
4
Date filed
10/19/2022, 05:14 PM
Previous filing
Sep 21, 2022
Next filing
Dec 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $6.78K +2.8K +6.61% $2.42* 45.1K Oct 17, 2022 Direct
transaction PCVX Common Stock Sale -$22.1K -874 -1.94% $25.31 44.3K Oct 17, 2022 Direct F1, F2
transaction PCVX Common Stock Sale -$49.9K -1.93K -4.35% $25.91 42.3K Oct 17, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -2.8K -1.25% $0.00 222K Oct 17, 2022 Common Stock 2.8K $2.42 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.68 to $25.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.685 to $26.205. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.